Discover
ALNY
Alnylam Pharmaceuticals, Inc.
220.06
1 x 219.57
1 x 219.79
bid
ask
+
3.08
1.42%
12:32 PM
timesize
| Ytd | -44.66% | |
| 1y | -49.41% |
216.50
day range
223.44
205.48
52 week range
491.22
| Open | 218.71 | Prev Close | 216.98 | Low | 216.50 | High | 223.44 | Mkt Cap | 29.45B |
| Vol | 514.59K | Avg Vol | 1.60M | EPS | 5.55 | P/E | 39.65 | Forward P/E | 17.40 |
| Beta | 0.30 | Short Ratio | 3.62 | Inst. Own | 102.17% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-30 | 50-d Avg | 278.68 | 200-d Avg | 341.55 | 1yr Est | 375.76 |
| Income Statement | |||
| Total Revenue | 1.29B | ||
| Revenues (USD) | 1.29B | ||
| Cost of Revenue | 298.45M | ||
| Gross Profit | 992.50M | ||
| Operating Expenses | 761.06M | ||
| Research and Development Expense | 413.13M | ||
| Selling, General and Administrative Expense | 347.92M | ||
| Operating Income | 231.44M | ||
| Interest Expense | 82.05M | ||
| Income Tax Expense | 13.31M | ||
| Net Income | 164.49M | ||
| Net Income Common Stock | 164.49M | ||
| Net Income Common Stock (USD) | 164.49M | ||
| Consolidated Income | 164.49M | ||
| Earnings per Basic Share | 1.23 | ||
| Earnings per Basic Share (USD) | 1.23 | ||
| Earnings per Diluted Share | 1.21 | ||
| Earning Before Interest & Taxes (EBIT) | 259.86M | ||
| Earning Before Interest & Taxes (USD) | 259.86M | ||
| Weighted Average Shares | 133.61M | ||
| Weighted Average Shares Diluted | 138.28M | ||
| Balance Sheet | |||
| Cash and Equivalents | 1.71B | ||
| Cash and Equivalents (USD) | 1.71B | ||
| Investments | 1.62B | ||
| Investments Current | 1.60B | ||
| Investments Non-Current | 22.17M | ||
| Trade and Non-Trade Receivables | 912.74M | ||
| Current Assets | 4.62B | ||
| Property, Plant & Equipment Net | 737.50M | ||
| Total Assets | 5.56B | ||
| Debt Current | 304.50M | ||
| Total Debt | 2.99B | ||
| Current Liabilities | 1.51B | ||
| Debt Non-Current | 2.68B | ||
| Total Liabilities | 4.20B | ||
| Accumulated Retained Earnings (Deficit) | -6.33B | ||
| Accumulated Other Comprehensive Income | -32.14M | ||
| Shareholders Equity | 1.35B | ||
| Shareholders Equity (USD) | 1.35B | ||
| Assets Non-Current | 938.60M | ||
| Total Debt (USD) | 2.99B | ||
| Deferred Revenue | 4.01M | ||
| Inventory | 97.11M | ||
| Liabilities Non-Current | 2.69B | ||
| Trade and Non-Trade Payables | 108.02M | ||
| Tax Assets | 113.79M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 13.90M | ||
| Net Cash Flow from Financing | 36.24M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -2.94M | ||
| Capital Expenditure | -34.68M | ||
| Issuance (Purchase) of Equity Shares | 33.56M | ||
| Issuance (Repayment) of Debt Securities | 2.68M | ||
| Net Cash Flow from Investing | -363.46M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -302.88M | ||
| Net Cash Flow from Operations | 326.72M | ||
| Effect of Exchange Rate Changes on Cash | -2.44M | ||
| Share Based Compensation | 86.63M | ||